Workweek October 17, 2023
Healthcare Headlines
GLP-1 Kidney Study News takes down Dialysis Names
- Novo Nordisk’s GLP-1 trial was testing whether the widely used diabetes drug, which contains the active ingredient semaglutide, could delay progression of chronic kidney disease and lower the risk of death from kidney and heart problems.
- The clinical trial was halted early because it was clear that the treatment would work for the designated population
- Consequently, dialysis stocks – and other healthcare services names – tanked after news on Novo Nordisk’s kidney trial involving Semaglutide hit the wire. DaVita, Fresenius, and Outset Medical stocks were down double digits on the week. DaVita even issued a statement on the matter.
- The potential clinical indications for GLP-1s are insane, and they...
Today's Sponsors
Today's Sponsor